Resonant Clinical Solutions expands European biorepository offerings with Creapharm Bioservices acquisition

Resonant Clinical Solutions, a global clinical solutions provider serving life sciences organizations, has expanded its biorepository offerings in Europe through the acquisition of Creapharm Bioservices, a French-based biobanking and cryogenic storage company. The acquisition, from Myonex, a global clinical trial supply and packaging company, bolsters Resonant’s ability to support complex clinical programs, particularly those involving cell and gene therapies.

Based in Bailly-Romainvilliers, France, Creapharm Bioservices specializes in biobanking and cryogenic storage for a variety of biotherapeutics and Advanced Therapy Medicinal Products (ATMPs). The company’s capabilities include vapor-phase nitrogen storage at -196°C, mechanical freezer and cold storage, and Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) compliant storage solutions. The acquisition aims to address the growing demand for specialized handling and storage as clinical pipelines increasingly focus on advanced modalities.

"Life sciences companies are increasingly seeking partners with the specialized expertise and global reach to support the entire clinical trial lifecycle," said Christophe Berthoux, CEO of Resonant Clinical Solutions. "Creapharm Bioservices strengthens our ability to support customers developing complex and sensitive therapies, while complementing our existing offerings in biorepository, kitting, and equipment and ancillary services."

The acquisition enhances Resonant’s global footprint, adding specialized expertise in cryogenic storage and handling of highly sensitive biological materials. Creapharm Bioservices brings with it a range of capabilities, including:

- Specialized cryogenic storage, with temperatures ranging from -196°C to -20°C. - Chain-of-custody from controlled room temperature to cryogenic storage. - Expertise supporting biotherapeutics and advanced therapies. - GMP/GDP-compliant infrastructure and quality capabilities. - Handling of Class 1 and Class 2 genetically modified organisms (GMOs). - Additional European infrastructure and customer relationships. - Technical expertise in the handling and storage of highly sensitive biological materials.

"We are excited to welcome the Creapharm Bioservices team and build on the strong technical knowledge and customer relationships they have established," said Corey Stone, Vice President and General Manager - Biorepository, Resonant Clinical Solutions.

Greg Lavin, CEO of Myonex, added, "Creapharm Bioservices is a natural fit for Resonant. Its specialized expertise is a strong complement to Resonant's global biorepository offering. This transaction allows Myonex to further concentrate on our core strengths and future strategy."

According to a study by IQVIA, non-small-molecule assets, including advanced modalities, accounted for 46% of Phase I, III clinical trial starts in 2024, up from 38% in 2019, underscoring the growing importance of specialized biorepository services.

Resonant Clinical Solutions, with its global presence and comprehensive clinical supply chain and sample lifecycle solutions, continues to support more than 2,500 clinical trials, facilitating over 20,000 customer-site shipments, and managing more than 100 million research assets in storage. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic and reference laboratories.

The financial terms of the transaction remain undisclosed.